(BMY) Bristol-Myers Squibb - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US1101221083
Stock:
Total Rating 50
Risk 75
Buy Signal 0.57
| Risk 5d forecast | |
|---|---|
| Volatility | 28.7% |
| Relative Tail Risk | -8.99% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.38 |
| Alpha | 6.97 |
| Character TTM | |
|---|---|
| Beta | 0.247 |
| Beta Downside | 0.517 |
| Drawdowns 3y | |
|---|---|
| Max DD | 40.94% |
| CAGR/Max DD | 0.03 |
EPS (Earnings per Share)
Revenue
Description: BMY Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 7.05b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA -0.79 > 1.0 |
| NWC/Revenue: 12.39% < 20% (prev 12.43%; Δ -0.04% < -1%) |
| CFO/TA 0.16 > 3% & CFO 14.16b > Net Income 7.05b |
| Net Debt (36.93b) to EBITDA (14.54b): 2.54 < 3 |
| Current Ratio: 1.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.04b) vs 12m ago 0.20% < -2% |
| Gross Margin: 67.65% > 18% (prev 0.57%; Δ 6708 % > 0.5%) |
| Asset Turnover: 52.77% > 50% (prev 52.16%; Δ 0.62% > 0%) |
| Interest Coverage Ratio: 7.08 > 6 (EBITDA TTM 14.54b / Interest Expense TTM 1.51b) |
Altman Z'' 2.06
| A: 0.07 (Total Current Assets 29.39b - Total Current Liabilities 23.42b) / Total Assets 90.04b |
| B: 0.19 (Retained Earnings 16.90b / Total Assets 90.04b) |
| C: 0.12 (EBIT TTM 10.69b / Avg Total Assets 91.32b) |
| D: 0.22 (Book Value of Equity 15.66b / Total Liabilities 71.53b) |
| Altman-Z'' Score: 2.06 = BBB |
Beneish M -3.26
| DSRI: 1.01 (Receivables 14.53b/14.42b, Revenue 48.19b/48.30b) |
| GMI: 0.84 (GM 67.65% / 56.80%) |
| AQI: 0.97 (AQ_t 0.57 / AQ_t-1 0.59) |
| SGI: 1.00 (Revenue 48.19b / 48.30b) |
| TATA: -0.08 (NI 7.05b - CFO 14.16b) / TA 90.04b) |
| Beneish M-Score: -3.26 (Cap -4..+1) = AA |
What is the price of BMY shares?
As of March 01, 2026, the stock is trading at USD 62.37 with a total of 20,740,738 shares traded.
Over the past week, the price has changed by +2.82%, over one month by +12.26%, over three months by +28.27% and over the past year by +11.43%.
Over the past week, the price has changed by +2.82%, over one month by +12.26%, over three months by +28.27% and over the past year by +11.43%.
Is BMY a buy, sell or hold?
Bristol-Myers Squibb has received a consensus analysts rating of 3.37.
Therefor, it is recommend to hold BMY.
- StrongBuy: 4
- Buy: 4
- Hold: 18
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the BMY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 61.8 | -1% |
| Analysts Target Price | 61.8 | -1% |
BMY Fundamental Data Overview February 28, 2026
P/E Trailing = 17.7101
P/E Forward = 7.5815
P/S = 2.5818
P/B = 5.3387
P/EG = 2.2562
Revenue TTM = 48.19b USD
EBIT TTM = 10.69b USD
EBITDA TTM = 14.54b USD
Long Term Debt = 42.85b USD (from longTermDebt, last quarter)
Short Term Debt = 2.46b USD (from shortTermDebt, last quarter)
Debt = 47.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 36.93b USD (from netDebt column, last quarter)
Enterprise Value = 161.36b USD (124.43b + Debt 47.14b - CCE 10.21b)
Interest Coverage Ratio = 7.08 (Ebit TTM 10.69b / Interest Expense TTM 1.51b)
EV/FCF = 12.56x (Enterprise Value 161.36b / FCF TTM 12.85b)
FCF Yield = 7.96% (FCF TTM 12.85b / Enterprise Value 161.36b)
FCF Margin = 26.65% (FCF TTM 12.85b / Revenue TTM 48.19b)
Net Margin = 14.63% (Net Income TTM 7.05b / Revenue TTM 48.19b)
Gross Margin = 67.65% ((Revenue TTM 48.19b - Cost of Revenue TTM 15.59b) / Revenue TTM)
Gross Margin QoQ = 67.23% (prev 71.89%)
Tobins Q-Ratio = 1.79 (Enterprise Value 161.36b / Total Assets 90.04b)
Interest Expense / Debt = 0.11% (Interest Expense 51.0m / Debt 47.14b)
Taxrate = 26.12% (384.0m / 1.47b)
NOPAT = 7.89b (EBIT 10.69b * (1 - 26.12%))
Current Ratio = 1.26 (Total Current Assets 29.39b / Total Current Liabilities 23.42b)
Debt / Equity = 2.55 (Debt 47.14b / totalStockholderEquity, last quarter 18.47b)
Debt / EBITDA = 2.54 (Net Debt 36.93b / EBITDA 14.54b)
Debt / FCF = 2.88 (Net Debt 36.93b / FCF TTM 12.85b)
Total Stockholder Equity = 17.96b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.72% (Net Income 7.05b / Total Assets 90.04b)
RoE = 39.27% (Net Income TTM 7.05b / Total Stockholder Equity 17.96b)
RoCE = 17.57% (EBIT 10.69b / Capital Employed (Equity 17.96b + L.T.Debt 42.85b))
RoIC = 11.92% (NOPAT 7.89b / Invested Capital 66.21b)
WACC = 4.97% (E(124.43b)/V(171.57b) * Re(6.82%) + D(47.14b)/V(171.57b) * Rd(0.11%) * (1-Tc(0.26)))
Discount Rate = 6.82% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.20%
[DCF] Terminal Value 87.00% ; FCFF base≈13.28b ; Y1≈14.24b ; Y5≈17.31b
[DCF] Fair Price = 233.5 (EV 512.48b - Net Debt 36.93b = Equity 475.55b / Shares 2.04b; r=5.90% [WACC]; 5y FCF grow 8.04% → 2.90% )
EPS Correlation: -12.32 | EPS CAGR: -12.29% | SUE: -1.59 | # QB: 0
Revenue Correlation: 59.09 | Revenue CAGR: 1.90% | SUE: 1.02 | # QB: 9
EPS next Quarter (2026-03-31): EPS=1.45 | Chg7d=+0.005 | Chg30d=+0.055 | Revisions Net=+1 | Analysts=21
EPS current Year (2026-12-31): EPS=6.25 | Chg7d=+0.013 | Chg30d=+0.267 | Revisions Net=+16 | Growth EPS=+1.6% | Growth Revenue=-2.7%
EPS next Year (2027-12-31): EPS=6.12 | Chg7d=+0.084 | Chg30d=+0.318 | Revisions Net=+8 | Growth EPS=-2.1% | Growth Revenue=-2.6%
[Analyst] Revisions Ratio: +0.09 (6 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.3% (Discount Rate 7.9% - Earnings Yield 5.6%)
[Growth] Growth Spread = -5.4% (Analyst -3.1% - Implied 2.3%)
P/E Forward = 7.5815
P/S = 2.5818
P/B = 5.3387
P/EG = 2.2562
Revenue TTM = 48.19b USD
EBIT TTM = 10.69b USD
EBITDA TTM = 14.54b USD
Long Term Debt = 42.85b USD (from longTermDebt, last quarter)
Short Term Debt = 2.46b USD (from shortTermDebt, last quarter)
Debt = 47.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 36.93b USD (from netDebt column, last quarter)
Enterprise Value = 161.36b USD (124.43b + Debt 47.14b - CCE 10.21b)
Interest Coverage Ratio = 7.08 (Ebit TTM 10.69b / Interest Expense TTM 1.51b)
EV/FCF = 12.56x (Enterprise Value 161.36b / FCF TTM 12.85b)
FCF Yield = 7.96% (FCF TTM 12.85b / Enterprise Value 161.36b)
FCF Margin = 26.65% (FCF TTM 12.85b / Revenue TTM 48.19b)
Net Margin = 14.63% (Net Income TTM 7.05b / Revenue TTM 48.19b)
Gross Margin = 67.65% ((Revenue TTM 48.19b - Cost of Revenue TTM 15.59b) / Revenue TTM)
Gross Margin QoQ = 67.23% (prev 71.89%)
Tobins Q-Ratio = 1.79 (Enterprise Value 161.36b / Total Assets 90.04b)
Interest Expense / Debt = 0.11% (Interest Expense 51.0m / Debt 47.14b)
Taxrate = 26.12% (384.0m / 1.47b)
NOPAT = 7.89b (EBIT 10.69b * (1 - 26.12%))
Current Ratio = 1.26 (Total Current Assets 29.39b / Total Current Liabilities 23.42b)
Debt / Equity = 2.55 (Debt 47.14b / totalStockholderEquity, last quarter 18.47b)
Debt / EBITDA = 2.54 (Net Debt 36.93b / EBITDA 14.54b)
Debt / FCF = 2.88 (Net Debt 36.93b / FCF TTM 12.85b)
Total Stockholder Equity = 17.96b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.72% (Net Income 7.05b / Total Assets 90.04b)
RoE = 39.27% (Net Income TTM 7.05b / Total Stockholder Equity 17.96b)
RoCE = 17.57% (EBIT 10.69b / Capital Employed (Equity 17.96b + L.T.Debt 42.85b))
RoIC = 11.92% (NOPAT 7.89b / Invested Capital 66.21b)
WACC = 4.97% (E(124.43b)/V(171.57b) * Re(6.82%) + D(47.14b)/V(171.57b) * Rd(0.11%) * (1-Tc(0.26)))
Discount Rate = 6.82% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.20%
[DCF] Terminal Value 87.00% ; FCFF base≈13.28b ; Y1≈14.24b ; Y5≈17.31b
[DCF] Fair Price = 233.5 (EV 512.48b - Net Debt 36.93b = Equity 475.55b / Shares 2.04b; r=5.90% [WACC]; 5y FCF grow 8.04% → 2.90% )
EPS Correlation: -12.32 | EPS CAGR: -12.29% | SUE: -1.59 | # QB: 0
Revenue Correlation: 59.09 | Revenue CAGR: 1.90% | SUE: 1.02 | # QB: 9
EPS next Quarter (2026-03-31): EPS=1.45 | Chg7d=+0.005 | Chg30d=+0.055 | Revisions Net=+1 | Analysts=21
EPS current Year (2026-12-31): EPS=6.25 | Chg7d=+0.013 | Chg30d=+0.267 | Revisions Net=+16 | Growth EPS=+1.6% | Growth Revenue=-2.7%
EPS next Year (2027-12-31): EPS=6.12 | Chg7d=+0.084 | Chg30d=+0.318 | Revisions Net=+8 | Growth EPS=-2.1% | Growth Revenue=-2.6%
[Analyst] Revisions Ratio: +0.09 (6 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 2.3% (Discount Rate 7.9% - Earnings Yield 5.6%)
[Growth] Growth Spread = -5.4% (Analyst -3.1% - Implied 2.3%)